A phase I/Ib study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) showed that the primary endpoint of overall response rate (ORR) was met for both combinations [30] (ClinicalTrials.gov number, NCT01192165). This evidence concerns the gene KRAS and non-small cell lung carcinoma.